Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386319516> ?p ?o ?g. }
- W4386319516 abstract "Mucociliary clearance is dysfunctional in people with primary ciliary dyskinesia, resulting in the accumulation of dehydrated mucus in the airways that is difficult to clear. We undertook a study to assess the benefit on lung function of treatment with a nebulised epithelial sodium channel (ENaC) blocker, idrevloride, with or without hypertonic saline, in people with primary ciliary dyskinesia.The CLEAN-PCD trial was a phase 2, randomised, double-blind, placebo-controlled crossover trial conducted at 32 tertiary adult and paediatric care centres and university hospitals in Canada, Denmark, Germany, Italy, the Netherlands, Poland, the UK, and the USA. People with a confirmed diagnosis of primary ciliary dyskinesia, aged 12 years or older, with a percentage of predicted FEV1 (ppFEV1) in the range of 40% to <90%, were randomly assigned in a 2:2:1:1 ratio (block size=6), stratified by ppFEV1 at screening, to one of four sequences: (1) idrevloride in hypertonic saline in treatment period 1 then hypertonic saline in treatment period 2; (2) hypertonic saline in treatment period 1 then idrevloride in hypertonic saline in treatment period 2; (3) idrevloride in treatment period 1 then placebo in treatment period 2; and (4) placebo in treatment period 1 then idrevloride in treatment period 2. The idrevloride dose was 85 μg and hypertonic saline was 4·2% NaCl. 3 mL of each study treatment was nebulised twice daily for 28 days in treatment periods 1 and 2; the two 28-day treatment periods were separated by a 28-day washout period. The primary endpoint was absolute change from baseline in ppFEV1 after 28 days. Safety assessments and reports of adverse events were made at clinic visits during each treatment period and by a follow-up telephone call 28 days after the last dose of study drug. Additionally, adverse events could be reported at a follow-up telephone call 3 days after the start of dosing and as they arose. Participants who received at least one dose of study drug were included in the safety analyses (safety set), and those who also had spirometry data were included in the efficacy analyses (full analysis set). The completed study is registered (EudraCT 2015-004917-26; ClinicalTrials.govNCT02871778).Between Sep 14, 2016, and May 31, 2018, 216 patients were screened and 123 were randomly assigned to one of four crossover sequences. Across the two treatment periods, treatment with idrevloride in hypertonic saline was initiated in 80 patients and completed in 78 patients (all 78 had data available and were included in the analysis); hypertonic saline initiated in 81 patients and completed in 76 patients (75 had data available and were included in the analysis); idrevloride initiated in 37 patients and completed in 35 patients (34 had data available and were included in the analysis); and placebo initiated in 36 patients and completed in 34 patients (all 34 had data available and were included in the analysis). Greater absolute increases in ppFEV1 from baseline to 28 days of treatment were seen with idrevloride in hypertonic saline (least-squares mean absolute change from baseline 1·0 percentage points, 95% CI -0·4 to 2·4) than with hypertonic saline alone (least-squares mean absolute change from baseline of -0·5 percentage points, -2·0 to 0·9; difference 1·5 percentage points, 95% CI <0·1 to 3·0; p=0·044). There was no significant difference in ppFEV1 for the parallel comparison of idrevloride in hypertonic saline compared with placebo or the crossover comparison of idrevloride with placebo. Adverse events were similar across treatments (57 to 65% of patients). Cough occurred in a greater proportion of participants during treatments that contained idrevloride or hypertonic saline compared with placebo, and oropharyngeal pain occurred in a greater proportion of participants during idrevloride treatments than during treatment with hypertonic saline alone or placebo, whereas chest discomfort was more common during treatments that included hypertonic saline.In this phase 2 crossover study, idrevloride in hypertonic saline was safe and associated with improved lung function over a 28-day period in people with primary ciliary dyskinesia compared with hypertonic saline alone. Larger, longer clinical studies are warranted to explore the potential benefits of idrevloride in combination with hypertonic saline in people with primary ciliary dyskinesia.Parion Sciences, under agreement with Vertex Pharmaceuticals." @default.
- W4386319516 created "2023-09-01" @default.
- W4386319516 creator A5004906447 @default.
- W4386319516 creator A5006880205 @default.
- W4386319516 creator A5010965488 @default.
- W4386319516 creator A5012209803 @default.
- W4386319516 creator A5013196415 @default.
- W4386319516 creator A5016528957 @default.
- W4386319516 creator A5020479008 @default.
- W4386319516 creator A5024240683 @default.
- W4386319516 creator A5024565318 @default.
- W4386319516 creator A5025603482 @default.
- W4386319516 creator A5030061739 @default.
- W4386319516 creator A5034835364 @default.
- W4386319516 creator A5036978097 @default.
- W4386319516 creator A5037784656 @default.
- W4386319516 creator A5038470848 @default.
- W4386319516 creator A5040391593 @default.
- W4386319516 creator A5041442452 @default.
- W4386319516 creator A5044665781 @default.
- W4386319516 creator A5047206366 @default.
- W4386319516 creator A5054459458 @default.
- W4386319516 creator A5055982974 @default.
- W4386319516 creator A5056291345 @default.
- W4386319516 creator A5057233234 @default.
- W4386319516 creator A5059576311 @default.
- W4386319516 creator A5059894362 @default.
- W4386319516 creator A5061029083 @default.
- W4386319516 creator A5065470994 @default.
- W4386319516 creator A5065521966 @default.
- W4386319516 creator A5066826190 @default.
- W4386319516 creator A5067780498 @default.
- W4386319516 creator A5069236537 @default.
- W4386319516 creator A5069537591 @default.
- W4386319516 creator A5073775080 @default.
- W4386319516 creator A5074478776 @default.
- W4386319516 creator A5074662522 @default.
- W4386319516 creator A5074665997 @default.
- W4386319516 creator A5078050470 @default.
- W4386319516 creator A5079524945 @default.
- W4386319516 creator A5080204019 @default.
- W4386319516 creator A5080216710 @default.
- W4386319516 creator A5081026957 @default.
- W4386319516 creator A5087699710 @default.
- W4386319516 creator A5088170255 @default.
- W4386319516 date "2023-08-01" @default.
- W4386319516 modified "2023-10-02" @default.
- W4386319516 title "Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial" @default.
- W4386319516 cites W1589654967 @default.
- W4386319516 cites W1833973206 @default.
- W4386319516 cites W2012248281 @default.
- W4386319516 cites W2035131077 @default.
- W4386319516 cites W2051828034 @default.
- W4386319516 cites W2083436606 @default.
- W4386319516 cites W2099449365 @default.
- W4386319516 cites W2103043501 @default.
- W4386319516 cites W2107060362 @default.
- W4386319516 cites W2109281756 @default.
- W4386319516 cites W2115068324 @default.
- W4386319516 cites W2122446730 @default.
- W4386319516 cites W2125078269 @default.
- W4386319516 cites W2129639344 @default.
- W4386319516 cites W2134387513 @default.
- W4386319516 cites W2142218173 @default.
- W4386319516 cites W2180161564 @default.
- W4386319516 cites W2337940600 @default.
- W4386319516 cites W2416461499 @default.
- W4386319516 cites W2417752611 @default.
- W4386319516 cites W2591075363 @default.
- W4386319516 cites W2795055822 @default.
- W4386319516 cites W2886868706 @default.
- W4386319516 cites W2920821402 @default.
- W4386319516 cites W2945205984 @default.
- W4386319516 cites W3011085182 @default.
- W4386319516 cites W3022967196 @default.
- W4386319516 cites W3083763949 @default.
- W4386319516 cites W4206183808 @default.
- W4386319516 cites W4233719888 @default.
- W4386319516 cites W4292199700 @default.
- W4386319516 doi "https://doi.org/10.1016/s2213-2600(23)00226-6" @default.
- W4386319516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37660715" @default.
- W4386319516 hasPublicationYear "2023" @default.
- W4386319516 type Work @default.
- W4386319516 citedByCount "1" @default.
- W4386319516 countsByYear W43863195162023 @default.
- W4386319516 crossrefType "journal-article" @default.
- W4386319516 hasAuthorship W4386319516A5004906447 @default.
- W4386319516 hasAuthorship W4386319516A5006880205 @default.
- W4386319516 hasAuthorship W4386319516A5010965488 @default.
- W4386319516 hasAuthorship W4386319516A5012209803 @default.
- W4386319516 hasAuthorship W4386319516A5013196415 @default.
- W4386319516 hasAuthorship W4386319516A5016528957 @default.
- W4386319516 hasAuthorship W4386319516A5020479008 @default.
- W4386319516 hasAuthorship W4386319516A5024240683 @default.
- W4386319516 hasAuthorship W4386319516A5024565318 @default.
- W4386319516 hasAuthorship W4386319516A5025603482 @default.
- W4386319516 hasAuthorship W4386319516A5030061739 @default.
- W4386319516 hasAuthorship W4386319516A5034835364 @default.
- W4386319516 hasAuthorship W4386319516A5036978097 @default.
- W4386319516 hasAuthorship W4386319516A5037784656 @default.